drugset
drugset / Trial / NCT03998345

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

NCT03998345 ↗

Unknown 24 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in the Patients with Locally advanced/Metastatic Solid Tumors in China.

Timeline

Start
2020-07-25
Primary completion
2020-12-24
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 609A Monoclonal antibody 1 mg/kg Intravenous
Subject 609A Monoclonal antibody 3 mg/kg Intravenous
Subject 609A Monoclonal antibody 10 mg/kg Intravenous
Subject 609A Monoclonal antibody 200 mg Intravenous
Subject 609A Monoclonal antibody 400 mg Intravenous

Indications

cancer